2002 Fiscal Year Final Research Report Summary
a novel therapy for metastatic liver cancer using cancer specific replicating HSV-1
| Project/Area Number |
13671356
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Osaka Medical College |
|---|
Principal Investigator |
TOYODA Masao Osaka Medical College Faculty of Medicine Associate Professor, 医学部, 助教授 (80207654)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TANIGAWA Nobuhiko Osaka Medical College Faculty of Medicine Professor, 医学部, 教授 (00111956)
OKUDA Junji Osaka Medical College Faculty of Medicine Assistant Professor, 医学部, 講師 (20278518)
MIYATAKE Shinichi Osaka Medical College Faculty of Medicine Associate Professor, 医学部, 助教授 (90209916)
|
|---|
| Project Period (FY) |
2001 – 2002
|
| Keywords | replicating HSV-1 / survivin / cancer specific promoter / CEA / metastatic liver cancer |
|---|
| Research Abstract |
The gene therapy using virus seems to be efficient for cancer therapy, but this strategy still remains insufficient for complete remission of tumor due to the low efficiency of viral delivery to whole cancer cells. In this study, we established recombinant HSV-1 (SurvHSV-1) which replication is restricted to cancer cells. For this purpose, we used the promoter of survivin, which expression is high specific to cancer cell. In single step assay of in vitro, SurvHSV-1 shows no amplification in fibroblast, which doesn't express survivin. On the other hand, amplification was recognized in HT29 or HepG2, which express survivin, but its replication was not enough to kill those cancer cell. In vivo study, viral treatment for metastatic liver cancer showed good inhibition of growth of Panc 1 expressing survivin, but it is not so effective as hrR3, which is ICP6 deficient recombinant HSV-1. In summary, Surv HSV-1 can amplify specifically in cancer cell, but its replication is too small to have oncolytic effect. To improve the activity of survivin promoter should lead to be more effective in this novel therapy for metastatic liver cancer.
|
